TY -的盟Struik劳拉·路易斯盟——Bottorff琼·L AU -巴斯克维尔体N布鲁斯盟——Oliffe约翰AU -克莱顿,苏珊PY - 2019 DA - 2019/03/07 TI -比较开发人员和最终用户的视角对戒烟支持通过粉碎渴望应用乔- JMIR Mhealth Uhealth SP - e10750六世- 7 - 3 KW -移动应用KW -戒烟KW -烟草控制KW -年轻人KW -定性研究AB -背景:终端用户的高吸烟率，加上他们的高应用使用率，使这个年龄段的人成为戒烟应用的特别忠实用户。越来越多的证据表明，应用程序是支持终端用户戒烟的有效途径。应用程序设计背后的期望如何与最终用户的需求和偏好保持一致，以及这是否因性别而异，人们知之甚少，这限制了评估和扩展这些干预措施的能力。目的:本定性案例研究的目的是在考虑性别影响的情况下，详细介绍以终端用户为目标的戒烟应用程序Crush The Crave (CTC)的整体设计方法与年轻成年女性和男性的观点和经验的比较。方法:对15名参与CTC开发的开发者和31名年轻的CTC用户进行半结构化访谈。对数据进行归纳分析，得出开发人员和最终用户对CTC的优缺点的看法。研究结果被分为4类(1)应用程序使用的技术和平台，(2)应用程序内容的基础，(3)应用程序的潜在焦点，(4)应用程序的外观，感觉和功能。结果:在应用程序使用的技术和平台类别下，发现开发者和最终用户都认为应用程序符合年轻成年吸烟者的需求和偏好。最终用户认为该技术的主要限制是频繁的“故障”和对互联网或数据的要求。对于应用内容的基础类别，开发者一致认为CTC的优势在于其强大的证据基础。 What mattered to end-users, however, was that the content was packaged positively, focusing on the benefits of quitting versus the consequences of smoking. It was found under the category, underlying focus of the app, that the individually-led focus of the app resonated with both developers and end-users, especially young men. Under the final category, look, feel and functionality of the app, it was found that developers were very positive about the app's aesthetics but end-users thought that the aesthetics incited a negative effect. Also, while end-users found it easy to use, they did not find the app intuitive. Finally, end-users thought that, because the app functions were largely based on a user’s quit date versus their ongoing efforts, this often lent to unmeaningful data. Conclusions: The current study findings highlight the importance of understanding multiple perspectives of stakeholders involved in a mobile-based intervention. By gathering the viewpoints of developers and end-users, both problematic and effective approaches that underlie development goals were revealed as a means of informing the development, implementation, and evaluation of future electronic health (eHealth) interventions. SN - 2291-5222 UR - https://mhealth.www.mybigtv.com/2019/3/e10750/ UR - https://doi.org/10.2196/10750 UR - http://www.ncbi.nlm.nih.gov/pubmed/30843864 DO - 10.2196/10750 ID - info:doi/10.2196/10750 ER -